DBV Technologies Completes Patient Enrollment in Pivotal VITESSE Phase 3 Trial for Peanut Allergy Patch
核心洞察
DBV Technologies has completed the last patient visit in its Phase 3 VITESSE clinical trial evaluating the VIASKIN Peanut patch in 654 peanut-allergic children aged 4-7 years.
The 12-month, double-blind, placebo-controlled study represents the largest treatment intervention study in peanut allergy, conducted across 86 sites in multiple countries.
The company remains on track to announce topline data from the trial in the fourth quarter of this year, marking a critical milestone for the epicutaneous immunotherapy approach.
DBV Technologies announced the completion of the last patient visit in its pivotal Phase 3 VITESSE clinical trial evaluating the VIASKIN Peanut patch for treating peanut allergies in children aged 4-7 years. The milestone positions the company to report topline data in the fourth quarter of this year, representing a critical step toward potential regulatory approval for this novel epicutaneous immunotherapy approach.
Largest Peanut Allergy Treatment Study Reaches Key Milestone
The VITESSE Phase 3 trial enrolled 654 subjects randomized 2:1 across 86 sites in the United States, Canada, Europe, the United Kingdom, and Australia, making it currently the largest treatment intervention study in peanut allergy. The 12-month, double-blind, placebo-controlled study has completed its treatment phase, evaluating both the efficacy and safety of the VIASKIN Peanut patch.
"Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut allergic children, their physicians and caregivers, if approved," stated Daniel Tassé, Chief Executive Officer of DBV Technologies.
Novel Epicutaneous Immunotherapy Approach
The VIASKIN patch represents a new class of non-invasive treatment through epicutaneous immunotherapy (EPIT), designed to introduce microgram amounts of biologically active compounds to the immune system through intact skin. This approach seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergens by leveraging the skin's immune tolerizing properties.
Food allergies are caused by hypersensitive immune reactions and characterized by symptoms ranging from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children, representing a significant unmet medical need in current treatment options.
Broader Clinical Development Program
Beyond the VITESSE trial, DBV Technologies maintains ongoing clinical trials of VIASKIN Peanut in peanut-allergic toddlers aged 1 through 3 years, expanding the potential treatment population across pediatric age groups. The company's food allergy programs focus on transforming care for food allergic patients through this innovative patch-based delivery system.
The French biopharmaceutical company, headquartered in Châtillon with North American operations in Warren, New Jersey, trades on both Euronext Paris and the Nasdaq Capital Market. With the completion of patient visits in VITESSE, the company moves closer to potentially bringing the first epicutaneous immunotherapy treatment for peanut allergies to market, pending successful trial results and regulatory approval.